1. A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma. Issue 19 (15th July 2015) Authors: Bendell, Johanna C.; Kelley, Robin K.; Shih, Kent C.; Grabowsky, Jennifer A.; Bergsland, Emily; Jones, Suzanne; Martin, Thomas; Infante, Jeffrey R.; Mischel, Paul S.; Matsutani, Tomoo; Xu, Shuichan; Wong, Lilly; Liu, Yong; Wu, Xiaoling; Mortensen, Deborah S.; Chopra, Rajesh; Hege, Kristen; Munste... Journal: Cancer Issue: Volume 121:Issue 19(2015) Page Start: 3481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study. Issue 9 (September 2020) Authors: Michot, Jean-Marie; Bouabdallah, Reda; Vitolo, Umberto; Doorduijn, Jeanette K; Salles, Gilles; Chiappella, Annalisa; Zinzani, Pier Luigi; Bijou, Fontanet; Kersten, Marie José; Sarmiento, Rafael; Mosulen, Silvia; Mendez, Cristina; Uttamsingh, Shailaja; Pourdehnad, Michael; Hege, Kristen; Chen, Tia... Journal: Lancet Issue: Volume 7:Issue 9(2020) Page Start: e649 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma. Issue 10 (24th August 2021) Authors: Rodriguez-Otero, Paula; Ayers, Dieter; Cope, Shannon; Davies, Faith E.; Delforge, Michel; Mojebi, Ali; Jansen, Jeroen P.; Weisel, Katja; Hege, Kristen; Dhanasiri, Sujith Journal: Leukemia & lymphoma Issue: Volume 62:Issue 10(2021) Page Start: 2482 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. Issue 1 (16th September 2014) Authors: Santegoets, Saskia JAM; Stam, Anita GM; Lougheed, Sinéad M; Gall, Helen; Jooss, Karin; Sacks, Natalie; Hege, Kristen; Lowy, Israel; Scheper, Rik J; Gerritsen, Winald R; van den Eertwegh, Alfons JM; de Gruijl, Tanja D Journal: Journal for immunotherapy of cancer Issue: Volume 2:Issue 1(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. (September 2022) Authors: Shah, Nina; Delforge, Michel; San-Miguel, Jesus; Moshkovich, Olga; Braverman, Julia; Dhanda, Devender S.; Lanar, Sally; Miera, Matthew; Williams, Agnes; Murphy, Ryan; Devlen, Jennifer; Hege, Kristen; Campbell, Timothy B.; Munshi, Nikhil C. Journal: Leukemia research Issue: Volume 120(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma. Issue 1 (14th January 2022) Authors: Ribrag, Vincent; Chavez, Julio C.; Boccomini, Carola; Kaplan, Jason; Chandler, Jason C.; Santoro, Armando; Corradini, Paolo; Flinn, Ian W.; Advani, Ranjana; Cassier, Philippe A.; Sangha, Randeep; Kenkre, Vaishalee P.; Isufi, Iris; Uttamsingh, Shailaja; Hagner, Patrick R.; Gandhi, Anita K.; Shen, ... Journal: EJHaem Issue: Volume 3:Issue 1(2022) Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗